Clinical trials: aldesleukin
Breast Cancer, Ovarian Cancer
Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00019916
- Testing
- aldesleukin, p53 peptide vaccine, in vitro-treated peripheral blood stem cell transplantation
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Melanoma
Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma
This study is to investigate safety and feasibility of a combination therapy of a tumor infiltrating lymphocytes (TIL) transfer with anti-programmed cell death protein (PD)-1 therapy in patients with metastatic melanoma that…
- Trial name
- BaseTIL (NCT04165967)
- Testing
- Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- University Hospital, Basel, Switzerland
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma
This phase I trial studies how well autologous NY-ESO-1-specific CD8-positive T lymphocytes (modified T lymphocytes [T cells]), chemotherapy, and aldesleukin with or without dendritic cell-targeting lentiviral vector ID-LV305…
- Conditions
- HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma, Recurrent Synovial Sarcoma
- Trial name
- NCT03450122
- Testing
- Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Anti-p53 TCR-Gene
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Background: The p53 gene normally suppresses tumor growth, but when it is mutated, or damaged, tumors can grow unchecked. In cancers where the p53 gene has mutated, an increased level of p53(overexpression of p53) can be measured…
- Trial name
- NCT00393029
- Testing
- anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase II trial to study the effectiveness of low-dose interleukin-2 in treating patients with metastatic or recurrent…
- Trial name
- NCT00002846
- Testing
- aldesleukin, conventional surgery
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Blumenthal Cancer Center at Carolinas Medical Center
Melanoma (Skin)
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00019721
- Testing
- MART-1 antigen, aldesleukin, gp100 antigen
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Colorectal Cancer
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or…
- Conditions
- Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Sarcoma
- Trial name
- NCT03935893
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Fludarabine + Cyclophosphamide combination
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Udai Kammula
HIV Infections
Effect of Interleukin-2 on HIV Treatment Interruption
Interleukin-2 (IL-2) helps the body make infection-fighting white blood cells, including CD4 and CD8 T cells. One HIV treatment strategy is planned treatment interruption (stopping anti-HIV drugs when CD4 count and level of virus…
- Trial name
- NCT00015704
- Testing
- Aldesleukin
- Where
- 17 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Versus Graft Host Disease
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
This research study is a way of gaining new knowledge about the treatment for cGVHD that has not responded to steroids. This research study is evaluating a drug called Interleukin-2 (IL-2) as a possible treatment for cGVHD.
- Trial name
- NCT02318082
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Renal Cell Carcinoma
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
The purpose of this study is to determine whether interleukin-2, interferon-alpha in combination with bevacizumab are effective in the treatment of metastatic renal cell carcinoma (mRCC).
- Trial name
- NCT01274273
- Testing
- Interleukin-2, Interferon Alfa-2b, Bevacizumab
- Where
- 2 sites in Denmark
- Volunteers
- 118 people
- Sponsor
- University of Aarhus
HER2-positive Breast Cancer, Male Breast Cancer
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00006228
- Testing
- trastuzumab, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Cryoglobulinemia Vasculitis
Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients
A systemic Vasculitis is found in 5 to 10% of HCV infected patients with mixed cryoglobulinemia (MC). It mainly involves the skin, peripheral nerve and the kidney and may be life threatening.
- Trial name
- NCT00574652
- Testing
- Proleukin
- Where
- France
- Volunteers
- 10 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Recurrent Melanoma, Stage IV Melanoma
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
This phase I trial studies the side effects and best dose of autologous T-antigen-presenting cells (T-APC) vaccine following therapeutic autologous lymphocytes (CTL) and cyclophosphamide in treating patients with metastatic…
- Trial name
- NCT01339663
- Testing
- cyclophosphamide, aldesleukin, autologous tumor cell vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Stage IIIB Melanoma, Stage IIIC Melanoma
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
The purpose of this study is to evaluate the efficacy of adjuvant adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin-2 (IL-2) after a nonmyeloablative lymphodepletion (NMA-LD) preparative…
- Conditions
- Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IIID Melanoma
- Trial name
- NCT06190249
- Testing
- LN-144, Cyclophosphamide, Mesna
- Sponsor
- James Isaacs, MD
Metastatic Melanoma
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
In this randomized controlled phase III study the investigators will evaluate whether TIL infusion preceded by non-myeloablative chemotherapy and followed by high dose bolus interleukin-2 can result in an improved progression…
- Trial name
- TIL (NCT02278887)
- Testing
- Translational research, Cyclophosphamide, Fludarabine
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 168 people
- Sponsor
- The Netherlands Cancer Institute
Lymphoma
Interleukin-2 in Treating Patients With Mycosis Fungoides
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides.
- Trial name
- NCT00002687
- Testing
- aldesleukin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Metastatic Cancer
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
Background: Carcinoembryonic antigen (CEA) is a protein present mostly in cancer cells. An experimental procedure developed for treating patients with cancer uses blood cells found in their tumors or bloodstream.
- Trial name
- NCT00923806
- Testing
- PG13-CEA_TCR (Anti-CEA TCR PBL), Aldesleukin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Renal Carcinoma, Renal Cell Carcinoma
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood…
- Conditions
- Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT06318871
- Testing
- Cytokine Induced Memory-like Natural Killer (CIML NK) Cells, Interleukin-2 (IL-2)
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Melanoma, Stage IV Melanoma
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
This phase I/II trial is studying the side effects of giving laboratory-treated T cells and ipilimumab together to see how well they work in treating patients with metastatic melanoma.
- Trial name
- NCT00871481
- Testing
- ipilimumab, cyclophosphamide, biopsy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsing Polychondritis
Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis
Relapsing polychondritis (RP) is a rare, systemic autoimmune disorder characterized by episodic inflammation of cartilaginous structures.
- Trial name
- NCT04077736
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University People's Hospital